For the quarter ended March 2025, SurModics (SRDX) reported revenue of $28.09 million, down 12.1% over the same period last year. EPS came in at -$0.13, compared to $0.07 in the year-ago quarter.

The reported revenue represents a surprise of -8.73% over the Zacks Consensus Estimate of $30.77 million. With the consensus EPS estimate being -$0.06, the EPS surprise was -116.67%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how SurModics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Product sales: $14.99 million compared to the $17.46 million average estimate based on two analysts. The reported number represents a change of -17.2% year over year.
• Revenue- Research, development and other: $3.19 million versus the two-analyst average estimate of $2.41 million. The reported number represents a year-over-year change of +30.1%.
• Revenue- Royalties and license fees: $9.91 million versus the two-analyst average estimate of $10.37 million. The reported number represents a year-over-year change of -13.2%.

View all Key Company Metrics for SurModics here>>>

Shares of SurModics have returned +0.1% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Surmodics, Inc. (SRDX) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research